Results 221 to 230 of about 88,666 (249)
Some of the next articles are maybe not open access.
Experimental Hematology, 2009
Acute myeloid leukemia (AML) is a heterogeneous disease with outcomes dependent upon several factors, including patient age, karyotype, mutational status, and comorbid conditions. For younger patients, approximately 60% to 80% achieve complete remission with standard therapy involving cytarabine and an anthracycline.
Joshua Shipley, James N. Butera
openaire +2 more sources
Acute myeloid leukemia (AML) is a heterogeneous disease with outcomes dependent upon several factors, including patient age, karyotype, mutational status, and comorbid conditions. For younger patients, approximately 60% to 80% achieve complete remission with standard therapy involving cytarabine and an anthracycline.
Joshua Shipley, James N. Butera
openaire +2 more sources
Critical Reviews in Oncology/Hematology, 1998
The incidence of acute myelogenous leukaemia (AML) increases steadily with age, more than 50% of the cases being diagnosed in subjects aged 60 years or over [1,2]. Age has been reported as an adverse prognostic indicator in AML affecting both remission rates and survival [1–3].
Gilbert B. Zulian, A Pinto, E Archimbaud
openaire +3 more sources
The incidence of acute myelogenous leukaemia (AML) increases steadily with age, more than 50% of the cases being diagnosed in subjects aged 60 years or over [1,2]. Age has been reported as an adverse prognostic indicator in AML affecting both remission rates and survival [1–3].
Gilbert B. Zulian, A Pinto, E Archimbaud
openaire +3 more sources
Current Opinion in Oncology, 1994
The Ph chromosome, the abnormality characteristic of chronic myelogenous leukemia, was discovered in 1963. However, the events responsible for the pathogenesis and transformation to accelerated and blastic phases are still unknown at the molecular level and are subjects of ongoing research.
Jorge E. Cortes, Susan O'Brien
openaire +3 more sources
The Ph chromosome, the abnormality characteristic of chronic myelogenous leukemia, was discovered in 1963. However, the events responsible for the pathogenesis and transformation to accelerated and blastic phases are still unknown at the molecular level and are subjects of ongoing research.
Jorge E. Cortes, Susan O'Brien
openaire +3 more sources
CONGENITAL MYELOGENOUS LEUKEMIA
Archives of Pediatrics & Adolescent Medicine, 1950Leukemia in the newborn is rare and unique in that it is almost invariably of the myelogenous type. Kelsey and Anderson,1in a comprehensive survey of the literature up to 1939, collected 17 reported cases of congenital leukemia. Of these, they accepted only 9 as instances of unquestionable congenital leukemia, the remaining 8 cases being probable ...
Leo J. Geppert, Fred M. Taylor
openaire +3 more sources
Photochemotherapy of myelogenous and non-myelogenous tumor cells
International Congress on Applications of Lasers & Electro-Optics, 1988Dye mediated laser photoradiation therapy was tested in an in vitro model for its efficacy to eliminate occult tumor cells for ex vivo autologous bone marrow purging. Merocyanine 540 was mixed with leukemia, lymphoma, small cell lung carcinoma, and multiple myeloma cells supplemented with 0.25% human albumin. This cell-dye mixture was exposed to 514 nm
openaire +2 more sources
Current Problems in Pediatric and Adolescent Health Care, 2002
~ cute myelogenous leukemia (AML) is characterized by the overproduction of immature myeloid cells in the bone marrow, which leads to bone marrow failure and infiltration of organs such as the liver and spleen. During the past several decades progress has been made in our knowledge of the biologic study and treatment of AML.
openaire +3 more sources
~ cute myelogenous leukemia (AML) is characterized by the overproduction of immature myeloid cells in the bone marrow, which leads to bone marrow failure and infiltration of organs such as the liver and spleen. During the past several decades progress has been made in our knowledge of the biologic study and treatment of AML.
openaire +3 more sources
Therapy of Acute Myelogenous Leukemia
Blood Reviews, 1983Over the past 10 years, there have been substantial advances in the treatment of AML. Intensive induction chemotherapy using 7-day courses of cytarabine and daunorubicin or amsacrine produce remission in 60% to 85% of patients. Median remission duration is 9 to 16 months. In some series, 20% to 40% of patients are in continuous remission for 2 years or
Gale Rp +3 more
openaire +4 more sources
Clinical Journal of Oncology Nursing, 2005
Chronic myelogenous leukemia (CML) represents about 14% of all leukemias and occurs with a frequency of about 1 in 100,000. It is rare in children. Symptoms include fatigue, weight loss, sweating, and abdominal discomfort from an enlarged spleen. The white blood cell count can range from 100-600 ul.
openaire +3 more sources
Chronic myelogenous leukemia (CML) represents about 14% of all leukemias and occurs with a frequency of about 1 in 100,000. It is rare in children. Symptoms include fatigue, weight loss, sweating, and abdominal discomfort from an enlarged spleen. The white blood cell count can range from 100-600 ul.
openaire +3 more sources
Current Opinion in Hematology, 1999
Over the past year, new information has been reported on the biology and treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by the breakpoint cluster region (BCR-ABL) chimeric gene, the product of which is p210BCR-ABL, a tyrosine kinase that gives hematopoietic cells the characteristics of excessive ...
U R, Osarogiagbon, P B, McGlave
openaire +2 more sources
Over the past year, new information has been reported on the biology and treatment of chronic myelogenous leukemia (CML). Chronic myelogenous leukemia is characterized by the breakpoint cluster region (BCR-ABL) chimeric gene, the product of which is p210BCR-ABL, a tyrosine kinase that gives hematopoietic cells the characteristics of excessive ...
U R, Osarogiagbon, P B, McGlave
openaire +2 more sources
Simplified method for the discrimination of acute myelogenous and non-myelogenous leukemias
Blut, 1983Rapid discrimination of acute myelogenous and non-myelogenous leukemias is of great importance when chemotherapy is urgently needed in severely ill patients. For decades the most reliable cytochemical method for this classification is the demonstration of myeloperoxidase in blast cells [1-4, 6, 7].
F. W. Hirsch +2 more
openaire +3 more sources